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Parkinson’s disease is a common neurodegenerative disorder caused by the degeneration
of midbrain substantia nigra dopaminergic neurons that project to the striatum. Despite
extensive investigation aimed at ﬁnding new therapeutic approaches, the dopamine pre-
cursor molecule, 3,4-dihydroxyphenyl-L-alanine (L-DOPA), remains the most effective and
commonly used treatment. However, chronic treatment and disease progression lead to
changes in the brain’s response to L-DOPA, resulting in decreased therapeutic effect and
the appearance of dyskinesias. L-DOPA-induced dyskinesia (LID) interferes signiﬁcantly
with normal motor activity and persists unless L-DOPA dosages are reduced to below ther-
apeutic levels. Thus, controlling LID is one of the major challenges in Parkinson’s disease
therapy. LID is the result of intermittent stimulation of supersensitive D1 dopamine recep-
tors located in the very severely denervated striatal neurons. Through increased coupling
to Gαolf, resulting in greater stimulation of adenylyl-cyclase, D1 receptors phosphorylate
DARPP-32, and other protein kinase A targets. Moreover, D1 receptor stimulation activates
extracellular signal-regulated kinase and triggers a signaling pathway involving mammalian
target for rapamycin and modiﬁcations of histones that results in changes in translation,
chromatin modiﬁcation, and gene transcription. In turn, sensitization of D1 receptor signal-
ing causes a widespread increase in the metabolic response to D1 agonists and changes in
the activity of basal ganglia neurons that correlate with the severity of LID. Importantly, dif-
ferent studies suggest that dyskinesias may share mechanisms with drug abuse and long
term memory involving D1 receptor activation. Here we review evidence implicating D1
receptor signaling in the genesis of LID, analyze mechanisms that may translate enhanced
D1 signaling into dyskinetic movements, and discuss the possibility that the mechanisms
underlying LID are not unique to the Parkinson’s disease brain.
Keywords: L-DOPA-induced dyskinesia, D1 dopamine receptor, Parkinson’s disease
Shortly after the recognition that l-DOPA in combination with
a peripheral decarboxylase inhibitor has a dramatic therapeutic
effect in Parkinson’s disease, it became clear that the treatment
was associated with major adverse effects like the appearance of
severely incapacitating abnormal involuntarymovements (Cotzias
et al., 1969; Papavasiliou et al., 1972). This raised concern about
the safety of the treatment and the consequences of beginning
l-DOPA therapy early in the course of the disease (Fahn, 1996),
but the fear that l-DOPA could be toxic was dispelled more than
a decade ago (Murer et al., 1999; Olanow et al., 2004). Cur-
rently, the principal candidates for the mechanism underlying
l-DOPA-induced dyskinesia (LID) are long term functional and
structural changes induced in the dopamine-depleted striatum by
dopamine-regulated signaling cascades (Jenner, 2008; Voon et al.,
2009; Cenci and Konradi, 2010).
Clinical studies have identiﬁed several factors that increase the
risk of LID: severity and/or duration of the disease, l-DOPA dose,
and intermittent l-DOPA dosing (Nutt, 2000, 2008). Studies in
patients indicate that initiating therapy with a selective D2-like
dopamine receptor agonist is associated with a very low risk of
developing dyskinesia, whereas D1-like agonists are very dysk-
inetogenic (Rascol et al., 2001, 2006; Holloway et al., 2004) in
agreement with recent ﬁndings in animal models of Parkinson’s
disease (Darmopil et al., 2009). Here we review animal studies
investigating the mechanisms of LID, with a focus on rodent
models and D1 receptor signaling mechanisms.
IS D1 RECEPTOR STIMULATION NECESSARY AND
SUFFICIENT TO INDUCE DYSKINESIA?
Early studies in primates suggested that D1-like agonists are less
likely than D2-like agonists to induce dyskinesia (Grondin et al.,
1997; Goulet and Madras, 2000). Indeed, it has been proposed that
stimulation of sensitized D2-like receptors may be necessary and
sufﬁcient to induce dyskinesia (Blanchet et al., 1995). However,
based on the administration of selective D1- or D2-like receptor
antagonists together with l-DOPA to MPTP-treated primates, it
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was concluded that neither the beneﬁcialmotor effects of l-DOPA,
nor LID, can be ascribed to stimulation of one receptor family
alone (Grondin et al., 1999). Currently, there is plenty of evidence
that the risk of dyskinesia is very low during chronic treatment
with a selective D2-like agonist in patients who have never been
exposed to l-DOPA (Damier et al., 2000; Holloway et al., 2004;
Rascol et al., 2006).
The discovery that rodents with a nigrostriatal lesion develop
LID provided a means to perform a non-pharmacological inter-
vention to study themechanisms underlying it. Rats andmicewith
unilateral nigrostriatal lesions induced by 6-hydroxydopamine
(6-OHDA) develop abnormal involuntary movements resem-
bling “peak-dose dyskinesia” after a few challenges with l-DOPA
(Andersson et al., 1999; Delﬁno et al., 2004; Pavon et al., 2006).
Pharmacological studies show that selective D1-like agonists have
more powerful dyskinetogenic effects than D2-like agonists, and
D1-like antagonists are more effective at inhibiting LID than D2-
like antagonists (Taylor et al., 2005; Delﬁno et al., 2007; Westin
et al., 2007). As in patients, de novo administration of a thera-
peutic dose of D2-like agonist produces mild or no dyskinesia
in 6-OHDA rats, but previous exposure to l-DOPA increases the
dyskinetogenic effect of selective D2 receptor stimulation (Delﬁno
et al., 2004; Larramendy et al., 2008).
Powerful evidence supporting a role for theD1R subtype in LID
has been provided in studies of genetically engineeredmice lacking
the D1 receptor (Darmopil et al., 2009). LID is completely blocked
in D1 knockouts with severe striatal dopaminergic denervation
induced by 6-OHDA (Figures 1 and 2). In contrast, D2R knock-
outs develop LID as easily as controls. Although the latter does not
rule out a possible contribution of D3R to LID expression (Bézard
et al., 2003), the fact that D1R knockouts do not show abnormal
involuntary movements with prolonged l-DOPA treatment sug-
gests that D1R stimulation is essential for the development of LID
(Figures 1 and 2).
The possibility remains that the D3R, which is abnormally
expressed in the dorsal striatum after repeated exposure to
FIGURE 1 | Genetic deletion of the D1 receptor precludes the
development of LID. Effect of the genetic deletion of the D1 receptor (A)
or D2 receptor (B) on scores of dyskinesia involving the forelimb, head and
trunk (“total dyskinesia score”). Adult wild type and knockout mice with
similar degrees of nigrostriatal denervation induced by intrastriatal
administration of the toxin 6-OHDA were treated daily with L-DOPA and
examined periodically for dyskinesia scores. See also Darmopil et al. (2009).
levodopa, contributes to LID expression (Bézard et al., 2003).
However, there is wide divergence between studies regarding the
extent of D3R upregulation and the effects of D3R preferring
antagonists and partial agonists on LID (Hurley et al., 1996; Bordet
et al., 1997; Quik et al., 2000; Hsu et al., 2004; Visanji et al., 2009).
Moreover, D1R stimulation induces a full repertoire of dyskinetic
movements resembling peak-dose dyskinesia even in the presence
of D3R antagonists (Kumar et al., 2009; Mela et al., 2010), sug-
gesting that D3R stimulation is not an obligatory requirement for
LID to occur. In summary, D1R stimulation seems to be necessary
for LID development and sufﬁcient to induce dyskinetic move-
ments. This is in agreement with data showing that, in contrast
to D2-like receptor agonists (most of which have a high afﬁn-
ity for the D3R – Rascol, 1999), D1-like receptor agonists are
markedly dyskinetogenic in monkeys rendered parkinsonian by
MPTP (Doucet et al., 1996) as well as in patients (Rascol et al.,
2001). Additional mechanisms involving D2 family receptors may
contribute to the expression of LID, especially when dyskinetic
movements are induced by D2-like agonists in animals previously
exposed to l-DOPA.
LID IS ASSOCIATED WITH CHANGES IN D1 RECEPTOR
SIGNALING IN THE DOPAMINE-DEPLETED STRIATUM
Early studies showing that deletion of the D1R gene blocks con-
trol of striatal prodynorphin expression and motor behavior by
cocaine and amphetamine called attention to D1R signaling in
behavioral sensitization to psychostimulants (Moratalla et al.,
1996a). This study also suggested involvement of the direct path-
way in psychostimulant sensitization, because prodynorphin is
a marker of those striatal “medium spiny” neurons (MSN) that
contain the D1 receptor and project to the substantia nigra. In
parallel, it has been shown that repeated administration of a D1-
like receptor agonist induces dyskinesia and the expression of the
transcription factors FosB/FosB in striatonigral MSNs (Doucet
et al., 1996). Further investigation showed that LID in the 6-OHDA
rat is associated with increased co-expression of FosB/FosB and
prodynorphin in striatal neurons (Andersson et al., 1999; see also
Sgambato-Faure et al., 2005; Pavon et al., 2006). In contrast to full-
length FosB proteins, which behave as immediate early genes, its
truncated forms called FosB show high stability and persist for
long periods (McClung et al., 2004). Although FosB cannot be
distinguished from FosB in immunocytochemical studies, Doucet
et al. (1996), Andersson et al. (1999), and Pavon et al. (2006) used
Western blotting to demonstrate that it is the truncated form,
FosB, which is up-regulated preferentially in LID. Importantly,
Andersson et al. (1999) provided causal evidence linking FosB
upregulation to LID, as intrastriatal infusion of fosB/fosB anti-
sense oligonucleotide inhibited the development of LID. Double
in situ hybridization studies using 35S- and digoxigenin-labeled
riboprobes showed that FosB/FosB inductionoccurred in striatal
neurons that contain D1R (Pavon et al., 2006), extending previous
ﬁndings showing co-expression of FosB/FosB with prodynor-
phin (Andersson et al., 1999). Interestingly, FosB expression is
inversely correlated with the abundance of dopamine ﬁbers in
the striatum and directly correlated with the severity of dyski-
nesia (Pavon et al., 2006), and it is blocked by pharmacological
or genetic inactivation of the D1 receptor (Westin et al., 2007;
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FIGURE 2 | L-DOPA does not induce dyskinesia in D1 receptor knockout
mice with severe nigrostriatal denervation. Frames extracted from videos
taken from representative 6-OHDA-lesioned wild type (A), D1−/− (B), and
D2−/− (C) mice, which have been treated with L-DOPA for 2weeks. The
sequence was taken 30min after an L-DOPA challenge and the frames are
0.15 s apart from each other. Reproduced from Darmopil et al., 2009.
Darmopil et al., 2009). The correlation betweenFosB induction
and the severity of LID has been corroborated in the MPTP
macaque model of Parkinson’s disease, in which overexpression of
a truncated formof JunD that acts as a dominant negative inhibitor
of FosB markedly reduces LID (Berton et al., 2009). Overall,
these ﬁndings show that LID is related to speciﬁc D1R-dependent
changes in gene expression in striatonigral MSNs neurons that
selectively express dynorphin and D1 receptor.
The fact that l-DOPA administration to naive animals does
not induceFosB expression and LID suggests that denervation-
induced supersensitivity of dopamine D1 receptors is at the core
of the mechanism leading to LID. Although D1 receptor super-
sensitivity is well documented in Parkinson’s disease, D1 receptor
expression does not change dramatically after nigrostriatal lesion
or repeated l-DOPA administration. However, D1 receptors may
be redistributed preferentially to the postsynaptic membrane and
cytoplasmic compartments involved in D1R trafﬁcking during
chronic l-DOPAadministration (Muriel et al., 1999;Guigoni et al.,
2007; Berthet et al., 2009). Moreover, D1 receptor supersensitiv-
ity in 6-OHDA rats and Parkinson’s disease patients is related to
increased levels of Gαolf (Corvol et al., 2004). Indeed, the ability
of D1-like receptor agonists to recruit G proteins in striatal tissue
is linearly related to dyskinesia scores in MPTP-lesioned monkeys
(Aubert et al., 2005).
There is also evidence that the resulting increase in cAMP pro-
duction is translated into effects on targets of the cAMP-dependent
protein kinase (PKA), like the Thr34 site of DARPP-32. The
striatum contains higher levels of phospho[Thr34]-DARPP-32 in
dyskinetic rats than in 6-OHDA rats that have not developed dysk-
inesia under l-DOPA treatment (Picconi et al., 2003). Moreover,
levels of phospho[Thr34]-DARPP-32 correlate with the severity of
dyskinesia in a mouse model of LID (Santini et al., 2007). Similar
changes in DARPP-32 phosphorylation have more recently been
found in MPTP-lesioned monkeys that have developed LID (San-
tini et al.,2010). Importantly, selective disruptionof theDARPP-32
gene in striatonigral neurons reduces LID, whereas a similar gene
disruption in striatopallidal neurons has no effect (Bateup et al.,
2010).
Phosphorylation at another speciﬁc target of PKA, the Ser845 in
the GluR1 subunit of AMPA receptors, is also increased in highly
dyskinetic mice and MPTP-lesioned monkeys, but not in con-
trol parkinsonian animals that have received l-DOPA but did not
develop substantial dyskinesia (Santini et al., 2007, 2010). More-
over, there is evidence that phosphorylation at Ser845 in GluR1 is
modulated by DARPP-32. Phospho[Thr34]-DARPP-32 is a potent
inhibitor of protein phosphatase-1 (PP-1), so, dephosphorylation
of targets of PP-1 should be reduced in LID. In agreement,DARPP-
32 knockouts not only exhibit reduced LID but also show reduced
phosphorylation at Ser845 in GluR1 (Santini et al., 2007).
Molecular changes related to LID have been detected in
other signaling cascades associated with dopamine D1/D5
receptor function, like the extracellular signal-regulated kinase
(ERK) 1/2 cascade (Figure 3). Indeed, D1R stimulation induces
ERK1/2 phosphorylation in the dopamine-intact (Valjent et al.,
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FIGURE 3 | Genetic inactivation of dopamine D1 receptor blocks
striatal molecular changes induced by chronic L-DOPA
administration in hemiparkinsonian mice. Photomicrographs of
adjacent coronal striatal sections fromWT (top) and D1R−/−
(bottom) hemiparkinsonian mice treated with L-DOPA. Sections are
immunostained for TH, FosB, Dynorphin, and p-ERK. Chronic
L-DOPA treatment induced marked FosB, Dynorphin, and p-ERK
expression in the striatal areas that are devoid of TH-immunoreactive
ﬁbers inWT mice, but not in the striatum of D1R−/− mice. Scale
bar=500μm.
2000; Mazzucchelli et al., 2002; Brami-Cherrier et al., 2005) and
dopamine-depleted brain (Gerfen et al., 2002). More recent work
established a correlation between ERK1/2 phosphorylation and
LID (Pavon et al., 2006; Santini et al., 2007; Westin et al., 2007;
Darmopil et al., 2009) and showed that pharmacological inhibi-
tion of the ERK1/2 signaling cascade reduces LID (Santini et al.,
2007; Schuster et al., 2008; Lindgren et al., 2009). Induction of
ERK1/2 phosphorylation by l-DOPA is blocked, in parallel with
LID, by D1/D5 receptor antagonists (Westin et al., 2007; Santini
et al., 2009a), and by genetic deletion of the speciﬁc D1 receptor
subtype (Darmopil et al., 2009), further supporting the require-
ment for the D1R subtype and the involvement of the direct
striatal outﬂow pathway. Finally, genetic interventions aimed at
reducing the activity of Ras-GRF1, a neuronal speciﬁc activator
of ERK signaling that mediates striatal ERK1/2 phosphorylation
in response to D1/D5R agonists (Fasano et al., 2009), reduced
LID in mice and monkeys (Fasano et al., 2010). As DARPP-32
knockouts also show reduced ERK1/2 phosphorylation, excessive
inhibition of PP-1 by phospho[Thr34]-DARPP-32 may contribute
to the higher levels of phospho-ERK1/2 in LID (Santini et al.,
2007).
ENHANCED D1R SIGNALING INDUCES CHANGES IN
TRANSLATION AND TRANSCRIPTION
It has been possible to follow the signaling cascade involved in LID
downstream to translation and transcription mechanisms.
In the denervated striatum, but not in the normal striatum,
l-DOPA administration induces phosphorylation of S6 kinase at
a site speciﬁcally regulated by themammalian target for rapamycin
(mTOR). S6 kinase phosphorylates S6, a ribosomal protein, and
the abundance of phosphorylated S6 kinase and S6 is linearly
related to the severity of LID. l-DOPA-induced S6 phosphory-
lation takes place in MSNs of the direct pathway and is blocked by
D1/D5R antagonists and rapamycin. Similar results were obtained
with another target of mTOR, eukaryotic translation initiation
factor 4E-binding protein (4E-BP), which when phosphorylated,
allows formation of a multiprotein complex with a critical role
in translation. Finally, inhibitors of the ERK signaling cascade
prevent phosphorylation of targets of mTOR, and rapamycin, an
inhibitor of mTOR signaling, reduces the development of LID
(Santini et al., 2009b).
Changes downstream of the ERK1/2 signaling cascade have
been detected in the MSN nucleus. Thr581 of the mito-
gen and stress-activated kinase-1 (MSK-1), a nuclear target of
ERK1/2, and histone H3, which is modiﬁed in response to
phospho[Thr581]MSK-1, are persistently activated in MSNs of
the direct pathway in rodents that develop LID (Darmopil et al.,
2009; Santini et al., 2009a). Induction of phospho-MSK-1 by l-
DOPAwas completely inhibited in animals pretreatedwithD1-like
antagonists (Westin et al., 2007). Moreover, D1-like antagonists
(Santini et al., 2009a) or genetic deletion of the D1R (Dar-
mopil et al., 2009), reduce histone H3 activation in parallel with
LID. Modiﬁed histone H3 is co-expressed with dynorphin and
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FosB/FosB in MSNs in highly denervated striatal areas in the
mousemodel of LID, further supporting that histoneH3modiﬁca-
tion is related to transcriptional changesmediating LID (Darmopil
et al., 2009).
Finally, some changes in transcriptionmaybe related to a switch
in gene expression control from cAMP-response element binding
transcription factor (CREB) dominance to FosB dependence.
In the intact striatum, prodynorphin transcription is mediated
by CREB, but l-DOPA induction of prodynorphin transcription
in parkinsonian rats is under the control of FosB and JunD
(Andersson et al., 2001).
CHANGES IN D2/D3 RECEPTOR-MEDIATED SIGNALING MAY
CONTRIBUTE TO THE EXPRESSION OF LID
Different lines of evidence suggest that D2R modulation of stri-
atopallidal neurons is not necessary for development of LID.
In D2R knockouts with 6-OHDA striatal lesions LID develops
with similar time course and intensity as in controls (Darmopil
et al., 2009). Moreover, selective genetic deletion of DARPP-32
in striatopallidal neurons has no effect on the development of
LID (Bateup et al., 2010). The above conclusion is reinforced by
the ﬁnding that there is a very low risk of dyskinesia associated
with administration of D2-like receptor agonists to patients or to
drug-naïve animals with nigrostriatal lesions (Delﬁno et al., 2004;
Holloway et al., 2004; Lundblad et al., 2005; Rascol et al., 2006).
By contrast, D2R antagonists that produce tardive dyskinesia in
patients, induce FosB/FosB expression in striatopallidal neurons
(Hiroi and Graybiel, 1996; Hiroi et al., 2002; Grande et al., 2004).
Thus, it seems likely that D2R subtype regulation of striatopal-
lidal neurons may modulate LID expression. This is illustrated in
a study by Gold et al. (2007) aimed at modulating D2 receptor sig-
naling in LID. Modifying the expression of regulator of G-protein
signaling (RSG) 9-2, a protein that inhibits D2 receptor interac-
tion with G proteins, regulated LID: RSG 9-2 knockouts showed
increased susceptibility to LID, whereas overexpression of RSG
9-2 reduced LID in MPTP-lesioned monkeys, and 6-OHDA rats.
However, the effects of modifying RSG 9-2 expression on motor
function were not speciﬁc to LID, suggesting that striatal D2R sub-
type signaling allows an increase in motor output that results in
more severe dyskinesia when the main LID signaling cascade, the
direct striatonigral pathway, is activated.
On the other hand, the D3R may directly modulate the main
LID signaling cascade. Repeated stimulation of D1Rby l-DOPAor
dopamine agonists in 6-OHDA rats leads to a progressive increase
in the expression of D3R in direct pathway MSNs, which paral-
lels sensitization of the rotational response to l-DOPA (Bordet
et al., 1997, 2000; see however Hurley et al., 1996; Quik et al.,
2000). Similar results were obtained in MPTP-lesioned monkeys
that have developed LID; further study showed that pharmacolog-
ical reduction of D3R activity reduced LID (Bézard et al., 2003; see
however Kumar et al., 2009; Mela et al., 2010). When co-expressed
in the same cell, D1R and D3R interact synergistically in the mem-
brane, with D3R stimulation enhancing D1-like agonist afﬁnity
and capacity to stimulate adenylyl cyclase (Fiorentini et al., 2008;
Marcellino et al., 2008). Recent work suggests that direct cross-talk
between D1R and D3R in the membrane reduces internalization
of D1R in response to dopamine, a mechanism that may normally
prevent excessive D1R activation (Berthet et al., 2009). It is worth
considering whether the effects of D3R preferring drugs in LID
result from their ability to modulate D1R-D3R membrane inter-
actions rather than from their antagonist/partial agonist action at
the ligand binding site.
LID IS ASSOCIATED WITH ALTERED SYNAPTIC PLASTICITY
IN THE STRIATUM
Although a causal connection has been established between
enhanced D1R signaling via ERK and LID, the functional changes
linking these molecular events to behavior remain poorly under-
stood. Once established, LID is very difﬁcult to reverse and very
easy to reestablish even after a long l-DOPA-free period (Nutt,
2000). Because of this, it has been suggested that long term changes
in brain circuits occur during chronic l-DOPA therapy (Calabresi
et al., 2000a) and dopamine denervation (Darmopil et al., 2009).
ERK’s established associationwith functional and structural forms
of synaptic plasticity is consistent with this (Thomas and Huganir,
2004).
The critical role played by dopamine in corticostriatal long term
potentiation (LTP) and LTD has been noticed 20 years ago (Cal-
abresi et al., 1992). Early work suggested that D1R stimulation is
necessary to induce LTP, whereas D2R stimulation is required for
LTD (Calabresi et al., 1992, 2000b; Centonze et al., 1999, 2003;
Tang et al., 2001). The mechanisms involved in LTP and LTD in
direct and indirect-pathwayMSNshavenot been studieduntil very
recently, with the availability of BAC transgenic mice expressing
ﬂuorescent proteins in speciﬁc neuronal populations (Wang et al.,
2006; Kreitzer and Malenka, 2007; Shen et al., 2008). LTD can
be readily induced in indirect pathway-MSNs via D2R-regulated
endocannabinoid release. Moreover, this LTD is disrupted in ani-
mal models of Parkinson’s disease and can be restored by D2-like
agonists and CB1 receptor stimulation (Kreitzer and Malenka,
2007; Shen et al., 2008). What happens in the direct pathway
neurons is less clear. One group could not induce LTD in direct
pathwayMSNs (Kreitzer andMalenka,2007).However,Wang et al.
(2006) andShen et al. (2008) have been able to induceLTD inD1R–
MSNs with different stimulation protocols. In rodent models of
Parkinson’s disease, LTD is favored over LTP in D1R–MSNs, but
protocols aimed at inducing LTD result in LTP in the presence of
D1-like agonists (Shen et al., 2008). The issue remains controver-
sial and has been addressed in recent excellent reviews (Kreitzer
and Malenka, 2008; Surmeier et al., 2009; Lovinger, 2010).
Concerning LID, there is evidence showing its association
with altered functional plasticity in corticostriatal synapses. A
pioneering slice study by Picconi et al. (2003) showed that exci-
tatory synapses in MSNs show normal LTP in l-DOPA-treated
6-OHDA rats, and that depotentiation is selectively impaired in
rats that have developed LID. As corticostriatal depotentiation
is prevented by D1-like agonists, it seems likely that enhanced
D1 signaling impedes depotentiation in dyskinetic rats. A deﬁcit
in depotentiation could lead to progressive enhancement of cor-
ticostriatal synaptic efﬁcacy in the direct pathway, resulting in
uncontrolled positive feedback to motor cortical areas (Figure 4).
Recent in vivo studies support the idea that depotentiation of
direct pathway MSNs is altered in 6-OHDA rats under chronic
l-DOPA therapy (Belujon et al., 2010). Unfortunately, no study
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FIGURE 4 | Mechanisms proposed to underlie LID.Top row diagrams:
sensitivity of direct and indirect-pathway MSNs to dopamine receptor
stimulation in a naive patient (left), in a patient that is ﬁnding beneﬁt under
L-DOPA therapy (middle), and in a dyskinetic patient (right). The naive
parkinsonian brain has hyperactive and hypoactive indirect and direct
pathways respectively, and may respond weakly to a ﬁrst challenge with
L-DOPA. Repeated D1 receptor stimulation may reinstate a balance between
the direct and indirect pathways and produce clinical beneﬁt (middle). In
advanced stages of the disease (right), the complete loss of dopamine
buffering capacity results in pulsatile stimulation of D1 receptors, more
surface expression of D1 receptors, induction of D3 receptor expression in
direct-pathway MSNs, and ampliﬁcation of D1 receptor signaling, leading to
dyskinesia. Bottom row diagrams: repeated pulsatile stimulation of D1
receptors in direct-pathway MSNs produces a multiplicative gain in the motor
response to L-DOPA, which is reﬂected in a change of the slope and an
increase in the maximal attainable response (left). This would progressively
impel the patient to the threshold for induction of dyskinesia. D2 receptor
stimulation in indirect-pathway MSNs may not drive the patient through the
dyskinesia threshold, but may have an additive effect if the patient is above
threshold (right). Moreover, once direct-pathway MSNs have crossed
threshold, stimulation of over-expressed D3 receptors may also have
multiplicative gain effects.
has yet taken advantage of engineered mice expressing ﬂorescent
proteins in D1R- or D2R–MSNs to establish how l-DOPA impacts
on plasticity in each striatal output pathway.
The ultimate mechanisms that block depotentiation have not
been clariﬁed; in fact, depotentiation itself is poorly understood.
It is well known that the D1R subtype has a facilitatory effect on
NMDA receptors in MSNs (Cepeda and Levine, 1998). The inter-
action with the NMDA receptor occurs through different mech-
anisms, including PKA/DARPP-32-mediated signaling and direct
protein–protein interactions in thepostsynapticmembrane,which
result in enhanced NMDA receptor currents and NMDA recep-
tor redistribution across dendritic spine compartments (Cepeda
and Levine, 2006). In animals with LID, NMDA receptors show-
ing altered subunit composition form complexes with D1R and
these complexes are trafﬁcked abnormally between the postsynap-
tic membrane and intracellular compartments or extrasynaptic
membrane sites (Fiorentini et al., 2006;Gardoni et al., 2006).How-
ever, it is not clear how such receptor reorganization is related to
alterations in synaptic plasticity or to other functional changes
associated with LID.
An aspect of NMDA receptor involvement in LID that has
not received much attention is that it also activates the ERK1/2
cascade (Thomas and Huganir, 2004). However, NMDA recep-
tor antagonists do not modify ERK phosphorylation induced
by D1-like agonists in the dopamine-depleted striatum (Gerfen
et al., 2002; Rylander et al., 2009). In contrast, mGluR5 antago-
nists attenuate LID and reduce ERK phosphorylation (Mela et al.,
2007; Rylander et al., 2009), suggesting that mGluR5 plays a more
important control over ERK1/2 than the NMDA receptor in the
parkinsonian condition. Thus, in LID, D1 receptor activation may
result in exaggerated ERK1/2 phosphorylation through multi-
ple mechanisms, including reduced activity of PP-1, enhanced
activity of Ras-GRF1, enhanced NMDA receptor, and mGluR5
activation.
In addition to alterations in functional plasticity, indirect evi-
dence suggests that LID is associated with structural changes in
neurons. Activity-regulated cytoskeletal-associated protein (arc)
is markedly up-regulated in direct pathway MSNs in rats with 6-
OHDA lesion treated chronically with l-DOPA, though it is not
clear that this change is selectively associated with the develop-
ment of LID (Sgambato-Faure et al., 2005). Although changes in
arc expression and function are frequently involved in synaptic
remodeling, further work is necessary to assess such changes in
LID.
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LID IS ASSOCIATED WITH WIDESPREAD FUNCTIONAL AND
STRUCTURAL CHANGES IN THE BASAL GANGLIA
There is evidence that angiogenesis and changes in the blood brain
barrier take place in parallel with LID in rats with nigrostriatal
lesion. This is manifest in enhanced proliferation of endothelial
cells, higher total microvessel length, and loss of blood brain bar-
rier markers across most basal ganglia structures in the denervated
hemisphere (Westin et al., 2006). The effect of l-DOPA on vessels
and behavior was mimicked by administration of D1-like agonists
andblockedbyD1-like antagonists,with drugs acting onD2 family
receptors having little or opposite effects.Moreover, pharmacolog-
ical inhibition of the ERK1/2 signaling cascade reduced both LID
and the microvascular changes induced by l-DOPA (Lindgren
et al., 2009). However, these changes in the blood brain barrier
were not corroborated by functional methods in a primate model
of LID (Astradsson et al., 2009), so more work is needed to under-
stand the functional signiﬁcance of these ﬁndings. Changes in
the microvasculature may be secondary to the higher metabolic
demands imposed by chronic D1R receptor stimulation in rats
with nigrostriatal lesion (Trugman and Wooten, 1986, 1987) or
result from more direct actions of dopamine agonists on blood
vessels (Hirano et al., 2008).
Widespread changes in metabolism and blood ﬂow have been
detected in LID. Rat pharmacological MRI studies revealed a
correlation between the severity of dyskinesia induced by D1
receptor stimulation and the magnitude of blood oxygenation
level-dependent signal (BOLD) in the striatum and motor cor-
tex (Delﬁno et al., 2007). Moreover, in 6-OHDA rats, the BOLD
response to D1 receptor stimulation showed sensitization with
repeated drug administration in both striatum and motor cortex
(Delﬁno et al., 2007). Similarly, nuclear magnetic resonance spec-
troscopy (NMR) studies in reserpinized animals showed increased
glutamatergic activity after l-DOPA treatment, associated with
increases in striatal c-fos expression and motor activity. These
responses are blocked in D1R knock out animals (Rodrigues et al.,
2007), suggesting the involvement of D1 receptor. Overall, these
results are consistentwith clinical ﬁndings. In patientswith PD, the
severity of involuntary arm and hand movements correlates with
increases in blood ﬂow measured with PET in the contralateral
motor cortex and basal ganglia (Brooks et al., 2000; Hirano et al.,
2008). In addition, l-DOPA-induced over-activation of the motor
cortex is not observed in drug-naïve hemiparkinsonian patients
(Buhmann et al., 2003). An interesting observation in pharma-
cological MRI studies is that a D3R-preferring agonist induces
regional cerebral blood volume changes similar to those induced
by D1-like agonists, but only if animals have developed LID. In the
absence of LID, the D3-preferring agonist has no effect (Sánchez-
Pernaute et al., 2007), further suggesting that D3R stimulation acts
by potentiating D1R signaling in LID.
Importantly, it seems that metabolic changes are not restricted
to motor areas. A 2-deoxyglucose accumulation study conducted
in MPTP-lesioned non-human primates revealed increased meta-
bolic activity in limbic and cognitive territories of the striatum
only in l-DOPA-treated animals that had developed dyskinesia
(Guigoni et al., 2005).
Less is known about the electrophysiological changes associ-
ated with the widespread metabolic effects occurring in LID. A
classic study by Filion et al. (1991) revealed a parallel between
the development of dyskinesia after repeated administration of
apomorphine to MPTP-lesioned monkeys and changes in neu-
ronal activity in the globus pallidus.Apomorphine, amixedD1/D2
agonist with a short plasma half-life that is known to be very dysk-
inetogenic in patients, did not induce dyskinesia and had small
effects on the activity of pallidal neurons inmonkeys beforeMPTP
lesioning. After induction of parkinsonism, however, repeated
administration of apomorphine led to growing motor side effects
and growing changes in pallidal activity. More speciﬁcally, dysk-
inesia was associated with a marked inhibition and reduction of
burst ﬁring in the internal segment of the globus pallidus (Filion
et al., 1991). This ﬁnding has been corroborated (Papa et al., 1999)
and extended by showing that dyskinesia induced by D1-like ago-
nists in the MPTP primate model has similar electrophysiological
correlates (Boraud et al., 2001). Moreover, a limited number of
recordings performed in patients undergoing functional neuro-
surgery also suggest that excessive inhibition of output neurons is
involved in dyskinesia (Merello et al., 1999; Lozano et al., 2000).
Overall, the data are consistent with the proposal that the gain of
direct pathway striatal neurons increases in LID (Figure 4).
The studies by Filion et al. (1991) and Boraud et al. (2001) show
that D2-like agonists induce dyskinesia and changes in pallidal
activity similar to those produced by apomorphine. In both studies
the samemonkeys were repeatedly challengedwith amixedD1/D2
agonist and a selective D2-like agonist, thus the D2 agonist effects
were taking place in a primed brain. Moreover, both apomor-
phine and D2-like receptor agonists induced increases in activity
in the external pallidal segment, which could have contributed to
reducing neuronal ﬁring in the internal pallidum. Thus, D2/D3
agonist-induced dyskinesia probably shares circuit mechanisms
with LID.
Although the data are consistent with the view that increased
gain of direct pathway striatal neurons produces excessive
inhibition of basal ganglia output, there is still no direct evidence
for this. Indeed, a recent study in drug-naïve 6-OHDA rats shows
that D1-like receptor stimulation produces a strong induction
of immediate early genes in the striatum without restoring the
response of direct pathwayMSNs to cortical stimulation to control
levels (Ballion et al., 2009). The possibility remains that the hypo-
thetical increase in the gain of corticostriatal connections requires
repeated exposure to l-DOPA or D1-like agonists. However, in
severely denervated 6-OHDA rats, a ﬁrst challenge with l-DOPA
can induce dyskinesia (see Onofrio et al., 1998, for similar ﬁndings
in patients). Further work correlating the activity of direct- and
indirect-pathway striatal MSNs to the degree of dopamine dener-
vation and dyskinesia scores is necessary to determine the circuit
mechanisms involved in LID.
ARE THE SIGNALING CHANGES OCCURRING IN LID UNIQUE
TO THE PARKINSONIAN BRAIN?
l-DOPA does not induce dyskinesia unless dopaminergic neurons
in the substantia nigra and striatal dopaminergic markers fall by
more than 90% (see for exampleWinkler et al., 2002). More recent
work correlating the spatial pattern of striatal denervation with
the molecular changes associated to LID showed that FosB/FosB
and prodynorphin induction is restricted to striatal areas where
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the density of dopaminergic ﬁbers drops below 5% of control lev-
els (Pavon et al., 2006; Darmopil et al., 2009). Thus, denervation
supersensitivity plays a pivotal role in the development of LID
by allowing the activation of non-canonical signaling cascades
by D1R stimulation, suggesting this is a mechanism unique to
LID. However, there is evidence that similar signaling mechanisms
are activated in dopamine-intact animals during sensitization to
psychostimulants and drugs of abuse. For instance, there is evi-
dence that a D1R-activated signaling cascade involving DARPP-32
and ERK1/2 phosphorylation, induction ofFosB, and prodynor-
phin expression, modiﬁcations of histone H3, a switch in gene
expression control from CREB-dependent to FosB-dependent,
and impaired LTD of corticostriatal synapses, is causally involved
in psychostimulant sensitization and drug addiction (Moratalla
et al., 1996a; Kelz et al., 1999; Valjent et al., 2000; McClung and
Nestler, 2003; Brami-Cherrier et al., 2005; Stipanovich et al., 2008;
Fasano et al., 2009; Kasanetz et al., 2010).
Although a point-by-point comparison between drug
addiction-related and LID-related mechanisms is beyond the
scope of this review, it seems clear that a large part of the sig-
naling cascade involved in LID can be activated in an intact brain
by cocaine and psychostimulants, although with much less inten-
sity and in considerably fewer striatal neurons (Moratalla et al.,
1996b; Pavon et al., 2006). This raises the question why l-DOPA
cannot activate it when the brain dopamine systems are intact.
The most plausible explanation is that pulsatile stimulation of D1
receptors is sufﬁcient to activate the non-canonical components
of the signaling cascade, but that the buffering capacity of even
a small number of dopaminergic terminals precludes l-DOPA
from producing the large variations in dopamine concentration in
the extracellular space that may be necessary to drive the cascade.
Indeed, l-DOPA induces slow and moderate changes in dopamine
concentration in the extracellular space when presynaptic mech-
anisms are intact but produces faster and more marked changes
in rodent models of Parkinson’s disease (Carta et al., 2006; Lind-
gren et al., 2010). Moreover, changes in dopamine concentration
are more marked in patients with more severe parkinsonism (de
la Fuente-Fernández et al., 2004). This is consistent with a recent
report showing that l-DOPA does not induce dyskinesia in rats
in which dopamine synthesis was knocked down but presynap-
tic dopaminergic terminals are preserved (Ulusoy et al., 2010).
Importantly, these rats show dyskinesia in response to apomor-
phine, a short plasma half-life D1/D2 agonist whose effect over
the dopamine receptors is not buffered by presynaptic terminals,
indicating that the postsynaptic mechanisms involved in LID are
functional. Moreover, the rats still do not show dyskinesia during
l-DOPA administration after receiving apomorphine challenges
that have been able to induce it (Ulusoy et al., 2010). In this
sense, striatal TH+ neurons that appear after severe denervation
and l-DOPA treatment are not able to provide enough buffering
capacity to reduce dyskinesias (Darmopil et al., 2008). Overall,
the data indicate that a good buffering capacity of dopamine
concentration in the extracellular space may preclude sensitiza-
tion to l-DOPA and attenuate the activation of already sensitized
postsynaptic dyskinesia machinery.
This is not to say that supersensitivity of D1R signaling
does not contribute to LID. Supersensitivity may explain why
the molecular changes associated to LID are several-fold more
widespread and intense than those induced by psychostimulants.
However, an almost complete loss of presynaptic dopaminergic
terminals (implying a loss of buffering capacity) is a prerequisite
for D1R signaling supersensitivity (Pavon et al., 2006; Darmopil
et al., 2009). Thus, D1R supersensitivity and the loss of buffering
capacity conspire together in LID.
DOES LID SHARE MECHANISMS WITH LONG TERM
MEMORY?
Recent ﬁndings linking D1 receptor stimulation to long term
memory storage further suggest that the signaling cascade involved
in LID is not unique to the parkinsonian brain, or even to the
striatum. Pharmacological studies show that blockade of D1-
like receptors at the time of encoding reduces the persistence of
hippocampal-dependent memories (O’Carroll et al., 2006; Bethus
et al., 2010). Also, intrahippocampal administration of D1-like
antagonists several hours after encoding blocks retention (Bern-
abeu et al., 1997). An important recent study shows that a long-
lasting fear memory disappears if hippocampal D1 receptors are
blocked 12 h after encoding, whereas a D1-like agonist applied at
the same post-training time turns a labilememory into a persistent
one (Rossato et al., 2009). Thus, sequential “waves” of dopamine
at different time points are critical for long term memory storage
in the hippocampus.
These pharmacological observations are backed up by stud-
ies in D1R knockout mice showing that this receptor subtype is
essential for spatial memory tasks (El-Ghundi et al., 1999). More-
over, D1 knockouts show spatial learning and associative learning
deﬁcits concurrent with a reduction in LTP (Granado et al., 2008;
Ortiz et al., 2010). Furthermore, mice in which hippocampal D1
receptors were knocked down with a small interfering RNA show
deﬁcits in spatial learning, fear learning, classical conditioning,
and LTP, ruling out effects of developmental adaptations in the D1
knockouts (Ortiz et al., 2010). Importantly, it has been shown that
D1R are important for both early- and late-LTP, indicating that
the D1R subtype is involved in different kinds of memory, includ-
ing new protein synthesis-independent and -dependent memory
(Granado et al., 2008; Ortiz et al., 2010). Further studies in vivo
showed that intact D1R are required for the acquisition of asso-
ciative learning and for the endogenous, non-stimulated, increase
in synaptic strength produced in the hippocampus during learn-
ing (Ortiz et al., 2010), supporting the important role of D1R in
learning and memory.
Elucidation of the signaling cascade mediating the role of D1R
in memory formation and retention is challenging, given the likely
contribution of several other neurotransmitters and modulators
that can share signaling mechanisms with dopamine. However,
there is evidence that EKR1/2phosphorylation (Bekinschtein et al.,
2008) and histone H3 acetylation (Levenson et al., 2004), as well as
Erg1 and Arc (Granado et al., 2008; Ortiz et al., 2010) are involved
in the retention of hippocampal memories. Thus, at least some
components of the signaling cascade implicated in LID are also
active in the hippocampus at times when D1 receptor stimulation
contributes to memory persistence.
An intriguing possibility is that phasic D1R stimulation is criti-
cal for inducing components of the signaling cascade that produce
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physiological increases in synaptic strength. Even in the striatum,
where tonic dopamine levels are relatively high, it is believed that
the low afﬁnity of D1R is not activated except during physiological
surges of dopamine induced by burst ﬁring of the dopaminergic
neurons (Gonon, 1997). Thus, physiological surges of dopamine
in the extracellular space could be involved in D1R promotion of
memory storage in different brain areas. Longer-lasting and more
marked non-physiological D1R stimulation induced by cocaine
andpsychostimulants in thedopamine-intact brain,or by l-DOPA
in the brain that has lost the buffering capacity of striatal dopamin-
ergic terminals, may induce abnormal plasticity and behavioral
alterations.
IMPLICATIONS FOR PARKINSON’S DISEASE THERAPY
Why does pulsatile activation of the D1 receptor signaling cas-
cade induce dyskinesia in Parkinson’s disease instead of other
behavioral abnormalities like addictive behaviors or impulse con-
trol disorders? The distinctive behavior resulting from pulsatile
dopaminergic stimulation in the parkinsonian brain may reﬂect a
preferential involvement of striatal motor areas, within which the
extreme but heterogeneous loss of dopamine buffering capacity
may produce a patchy pattern of molecular and functional post-
synaptic changes (Darmopil et al., 2009). This non-physiological
patchy pattern of plasticity would distort the ﬂow of cortical infor-
mation through the direct basal ganglia pathway, giving rise to
abnormal movements instead of behavioral stereotypies. In this
context, over-activation of dopamine signaling cascades in areas
that are not so extensively denervated in Parkinson’s disease, like
the ventral striatum and frontal cortex, may lead to behavioral
abnormalities that are not unique to the parkinsonian brain, like
addiction to l-DOPA, pathological gambling, and other impulse
control disorders (Dagher andRobbins,2009). This hypothesis can
be interrogated by studying the behavioral consequences of inter-
mittent stimulation of dopamine receptors after manipulating
dopamine buffering capacity in speciﬁc brain areas.
This view opens questions about future directions in Parkin-
son’s disease therapy. If the postsynaptic signaling involved in
LID is not unique but part of physiological rewarding and mem-
ory storage mechanisms, targeting the non-canonical components
of the signaling cascade may have undesirable consequences on
behavior. In this context, increasing l-DOPA buffering capacity in
the motor district of the striatum emerges as a more etiologically-
and physiologically-rooted approach to the treatment of Parkin-
son’s disease, of which the concept of “continuous dopaminergic
stimulation” (Olanow et al., 2006) can be seen as an antecedent.
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